JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera-Reference-Cited by-同舟云学术

JAK2V617F allele burden and thrombosis: A direct comparison in essential thrombocythemia and polycythemia vera

Published:2009-09 Issue:9 Volume:37 Page:1016-1021
ISSN:0301-472X
Container-title:Experimental Hematology
language:en
Short-container-title:Experimental Hematology

Author:

Carobbio Alessandra,Finazzi Guido,Antonioli Elisabetta,Guglielmelli Paola,Vannucchi Alessandro M.,Dellacasa Chiara M.,Salmoiraghi Silvia,Delaini Federica,Rambaldi Alessandro,Barbui Tiziano

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Genetics,Hematology,Molecular Biology

Reference21 articles.

1. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders;Baxter;Lancet,2005

2. A gain-of-function mutation of JAK2 in myeloproliferative disorders;Kralovics;N Engl J Med,2005

3. Clinical Correlates of JAK2 V617F Allele Burden in Essential Thrombocythemia;Kittur;Cancer,2007

4. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study;Campbell;Lancet,2005

5. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders;Pardanani;Blood,2008

Cited by 88 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of JAK2V617F allele burden and clinical correlates in polycythemia vera: a systematic review and meta-analysis;Annals of Hematology;2024-04-23

2. Approach to Diagnosis of BCR::ABL1-Negative Myeloproliferative Neoplasms;Indian Journal of Medical and Paediatric Oncology;2023-11-27

3. Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management;American Journal of Hematology;2023-06-26

4. Essential Thrombocythemia in Adolescents and Young Adults: Clinical Aspects, Treatment Options and Unmet Medical Needs;Current Treatment Options in Oncology;2023-05-17

5. The Combination of JAK2V617F Allele Burden and WT1 Expression can Be Helpful in Distinguishing the Subtype of MPN Patients;Cancer Control;2023-03-09